EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors

L L Siu, M E Gutierrez, L Pudelko, K Ruth, M A F N Filho, R Zaynagetdinov, P Hu, T Kitzing, B K Guenhan, I Durutovic, M McKean

ESMO Open · 2026-05 · 11 (5) · 106962

DOI: 10.1016/j.esmoop.2026.106962 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift ESMO Open, 2026-05. Verfasst von L L Siu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address: lillian.siu@uhn.ca. Hauptthemen laut MEDLINE: Neoplasms, Adenosine A2 Receptor Antagonists, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAdenosine A2 Receptor AntagonistsAntineoplastic AgentsHumansFemaleMaleMiddle AgedAgedAdultMaximum Tolerated DoseReceptor, Adenosine A2AReceptor, Adenosine A2B

Stichwörter der Autor:innen

advanced solid tumorsdual A(2)(A)/A(2)(B) adenosine receptor antagonistfirst-in-humanmuvadenant (M1069)pharmacokineticssafety

Substanzen

Adenosine A2 Receptor AntagonistsReceptor, Adenosine A2AReceptor, Adenosine A2BAntineoplastic Agents

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address: lillian.siu@uhn.ca.
  • Hackensack University Medical Center, Hackensack, USA.
  • Merck Healthcare KGaA, Darmstadt, Germany.
  • EMD Serono Research & Development Institute Inc, Billerica, USA, an affiliate of Merck KGaA.
  • Sarah Cannon Research Institute (SCRI), Nashville, USA.

Förderung

  • Merck

Zitieren

APA

Siu, L. L., Gutierrez, M. E., Pudelko, L., Ruth, K., Filho, M. A. F. N., Zaynagetdinov, R., Hu, P., Kitzing, T., Guenhan, B. K., Durutovic, I., & McKean, M. (2026). First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors. ESMO Open, 11(5), 106962. https://doi.org/10.1016/j.esmoop.2026.106962

Vancouver

Siu LL, Gutierrez ME, Pudelko L, Ruth K, Filho MAFN, Zaynagetdinov R, et al. First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors. ESMO Open. 2026;11(5):106962. doi:10.1016/j.esmoop.2026.106962

BibTeX
@article{Siu2026,
  author = {Siu, L L and Gutierrez, M E and Pudelko, L and Ruth, K and Filho, M A F N and Zaynagetdinov, R and Hu, P and Kitzing, T and Guenhan, B K and Durutovic, I and McKean, M},
  title = {First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors},
  journal = {ESMO Open},
  year = {2026},
  volume = {11},
  number = {5},
  pages = {106962},
  doi = {10.1016/j.esmoop.2026.106962}
}
Kostenlos starten →